Setareh Shamsili News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Setareh shamsili. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Setareh Shamsili Today - Breaking & Trending Today

Setareh Shamsili resigned as a board member of Ryvu Therapeutics

Setareh Shamsili resigned as a board member of Ryvu Therapeutics
biznespolska.pl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biznespolska.pl Daily Mail and Mail on Sunday newspapers.

Setareh Shamsili , Axel Glasmacher , Ryvu Therapeutics ,

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Nordrhein Westfalen , Setareh Shamsili , Axel Glasmacher , Pawel Przewiezlikowski , Competent Authority , Drug Administration , Head Of The Global Clinical Research , Warsaw Stock Exchange , Cancer Drug Development Forum , Development Hematology Oncology At Celgene , Leukemia Lymphoma Society Therapy Acceleration Program , University Of Bonn , Congress On , Menarini Group , Ethics Committee , Chief Executive Officer , Executive Vice President , Management Board , Chief Medical Officer , Ryvu Supervisory Board Member , Supervisory Board , Cancer Drug Development , Senior Vice President , Global Clinical Research , Development Hematology Oncology , Lymphoma Society Therapy Acceleration Program ,

SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Share this article
Share this article
KRAKOW, Poland, June 1, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) today announced that the latest results from the DIAMOND-01 clinical trial (CLI24-001; clinicaltrials.gov identifier NCT03008187) will be disclosed through poster presentations at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses, to be held on June 4-8, and June 9-17, respectively.
DIAMOND-01 is a First-in-Human, Phase I/II, dose escalation and cohort expansion trial of SEL24 (MEN1703), a first in class, orally available, dual PIM/FLT3 inhibitor in-licensed by Menarini Group from Ryvu Therapeutics, which is currently investigated as single agent for the treatment of patients with Acute Myeloid Leukemia (AML). ....

United States , Dirk Laurent , Setareh Shamsili , Menarini Ricerche , American Society Of Clinical Oncology , Menarini Group , European Hematology Association , Warsaw Stock Exchange , Ryvu Therapeutics , American Society , Clinical Oncology , Virtual Congresses , Acute Myeloid Leukemia , Global Therapeutic Area Head , Chief Medical Officer , Hematologic Malignancies , Myelodysplastic Syndromes , Human Study , Acute Myeloid , ஒன்றுபட்டது மாநிலங்களில் , டர்க் பரிசு பெற்றவர் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , ஐரோப்பிய ஹீமாட்டாலஜி சங்கம் , வார்சா ஸ்டாக் பரிமாற்றம் , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் ,

Ryvu Therapeutics obtains Poland nod for Phase I/II cancer study

Ryvu Therapeutics has received approval from the Polish regulator for a Phase I/II clinical trial of RVU120 (SEL120) to treat solid tumours. ....

Setareh Shamsili , Central Ethics Committee , Drug Administration , Office For Registration Of Medicinal Products , Ryvu Therapeutics , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , மைய நெறிமுறைகள் குழு , அலுவலகம் க்கு பதிவு ஆஃப் மருத்துவ ப்ராடக்ட்ஸ் , போலீஷ அலுவலகம் , மருத்துவ ப்ராடக்ட்ஸ் , மருத்துவ சாதனங்கள் ,

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
News provided by
Share this article
Share this article
KRAKOW, Poland, May 28, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that its Clinical Trial Application (CTA) to commence a single-agent, open-label Phase I/II trial, investigating the safety and efficacy of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland, has been fully approved by the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, and the respective Central Ethics Committee. ....

United States , Setareh Shamsili , Central Ethics Committee , Leukemia Lymphoma Society Therapy Acceleration Program , Menarini Group , Drug Administration , Warsaw Stock Exchange , Office For Registration Of Medicinal Products , Ryvu Therapeutics , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Triple Negative Breast Cancer , Chief Medical Officer , Clinical Trial Applications , Lymphoma Society Therapy Acceleration Program , ஒன்றுபட்டது மாநிலங்களில் , மைய நெறிமுறைகள் குழு , லுகேமியா லிம்போமா சமூகம் சிகிச்சை விரைவுபடுத்துதல் ப்ரோக்ர்யாம் , வார்சா ஸ்டாக் பரிமாற்றம் , அலுவலகம் க்கு பதிவு ஆஃப் மருத்துவ ப்ராடக்ட்ஸ் , மருத்துவ சோதனை விண்ணப்பம் , போலீஷ அலுவலகம் ,